aTyr Pharma ATYR 深 滬
等待開盤 12-19 09:30:00 美东时间
0.7031
-0.006
-0.92%
華盛通- 最 高0.748
- 今 開0.7096
- 成交量 167.31万股
- 最 低 0.70
- 昨 收 0.7096
- 總市值 6889.44万
- 52周最高 7.2904
- 市盈率 靜 --
- 換手率 1.71%
- 52周最低 0.64
- 委 比 -85.71%
- 總股本 9798.66万
- 歷史最高 396.06
- 量 比 0.99
- 振 幅 6.76%
- 歷史最低 0.64
- 每 手 1
- 風險率 1.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多The Short List — Top 10 Most Shorted Stocks Right Now
Here's a look at the top ten most shorted stocks in the market right now, including Wendy's, Lucid and Wolfspeed.
11-27 00:34
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns
Aclass actionlawsuit was filed againstaTyr Pharma ($ATYR) on ...
11-25 23:09
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $1
RBC Capital analyst Brian Abrahams maintains aTyr Pharma (NASDAQ:ATYR) with a Sector Perform and lowers the price target from $1.5 to $1.
11-08 03:37
Symbotic, Serve Robotics, AeroVironment, aTyr Pharma, Cummins: Insider Moves Unveiled
Insiders have been trading these 5 stocks: (($SYM)), (($SERV)), (($AVAV)), (($A...
10-11 21:00
aTyr Pharma Faces Legal Storm After Trial Failure
In a dramatic turn of events, aTyr Pharma, Inc. finds itself at the center of a...
10-10 21:15
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
SAN FRANCISCO, Oct. 9, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's s...
10-10 10:18
aTyr Pharma Highlights Trial Results For Efzofitimod, Aiming To Ease Fatigue And Steroid Use In Pulmonary Sarcoidosis
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today
09-30 17:32
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
aTyr Pharma announced positive results from its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis patients. The study showed significant improvements in fatigue and general health scores compared to placebo, though it missed its primary endpoint of reducing oral corticosteroid use. Efzofitimod demonstrated potential to improve multiple disease-related outcomes and reduce reliance on chronic steroids, offering hope for better quality ...
09-30 09:30
